Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

The ceRNA network of lncRNA and miRNA in lung cancer

  • Seo, Danbi (Department of Science Education, Korea National University of Education) ;
  • Kim, Dain (Department of Science Education, Korea National University of Education) ;
  • Chae, Yeonsoo (Department of Science Education, Korea National University of Education) ;
  • Kim, Wanyeon (Department of Science Education, Korea National University of Education)
  • Received : 2020.12.03
  • Accepted : 2020.12.10
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Since lung cancer is a major causative for cancer-related deaths, the investigations for discovering biomarkers to diagnose at an early stage and to apply therapeutic strategies have been continuously conducted. Recently, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are being exponentially studied as promising biomarkers of lung cancer. Moreover, supportive evidence provides the competing endogenous RNA (ceRNA) network between lncRNAs and miRNAs participating in lung tumorigenesis. This review introduced the oncogenic or tumor-suppressive roles of lncRNAs and miRNAs in lung cancer cells and summarized the involvement of the lncRNA/miRNA ceRNA networks in carcinogenesis and therapeutic resistance of lung cancer.

Keywords

References

  1. Romaszko AM, Doboszynska A. Multiple primary lung cancer: a literature review. Adv Clin Exp Med 2018;27:725-730. https://doi.org/10.17219/acem/68631
  2. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007;75:56-63.
  3. Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, et al. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung Cancer 2017;112:156-164. https://doi.org/10.1016/j.lungcan.2017.08.011
  4. Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am 2019;31:303-313. https://doi.org/10.1016/j.cnc.2019.05.002
  5. Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci 2019;44:33-52. https://doi.org/10.1016/j.tibs.2018.09.012
  6. Nigita G, Marceca GP, Tomasello L, Distefano R, Calore F, Veneziano D, et al. ncRNA editing: functional characterization and computational resources. Methods Mol Biol 2019;1912:133-174. https://doi.org/10.1007/978-1-4939-8982-9_6
  7. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer 2018;18:5-18. https://doi.org/10.1038/nrc.2017.99
  8. Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA-lncRNA interactions. Methods Mol Biol 2016;1402:271-286. https://doi.org/10.1007/978-1-4939-3378-5_21
  9. Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform 2014;15:1-19. https://doi.org/10.1093/bib/bbs075
  10. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 2019;234:5451-5465. https://doi.org/10.1002/jcp.27486
  11. Bak RO, Mikkelsen JG. miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 2014;5:317-333.
  12. Vaschetto LM. miRNA activation is an endogenous gene expression pathway. RNA Biol 2018;15:826-828.
  13. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer: a brief overview. Adv Biol Regul 2015;57:1-9. https://doi.org/10.1016/j.jbior.2014.09.013
  14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013
  15. Sandiford OA, Moore CA, Du J, Boulad M, Gergues M, Eltouky H, et al. Human aging and cancer: role of miRNA in tumor microenvironment. Adv Exp Med Biol 2018;1056:137-152. https://doi.org/10.1007/978-3-319-74470-4_9
  16. Iacona JR, Lutz CS. miR-146a-5p: Expression, regulation, and functions in cancer. Wiley Interdiscip Rev RNA 2019;10:e1533. https://doi.org/10.1002/wrna.1533
  17. Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci 2018;75:3539-3551. https://doi.org/10.1007/s00018-018-2877-x
  18. Shen YY, Cui JY, Yuan J, Wang X. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci 2018;22:5554-5561.
  19. Jiang YJ, Bikle DD. LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol 2014;144 Pt A:87-90. https://doi.org/10.1016/j.jsbmb.2013.11.018
  20. Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med 2018;22:5768-5775. https://doi.org/10.1111/jcmm.13866
  21. Do H, Kim W. Roles of Oncogenic long non-coding RNAs in cancer development. Genomics Inform 2018;16:e18. https://doi.org/10.5808/GI.2018.16.4.e18
  22. Ma Y, Zhang J, Wen L, Lin A. Membrane-lipid associated lncRNA: a new regulator in cancer signaling. Cancer Lett 2018;419:27-29. https://doi.org/10.1016/j.canlet.2018.01.008
  23. Wang X, Yin H, Zhang L, Zheng D, Yang Y, Zhang J, et al. The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer. J Thorac Dis 2019;11:1772-1778. https://doi.org/10.21037/jtd.2019.05.69
  24. Seo D, Kim D, Kim W. Long non-coding RNA linc00152 acting as a promising oncogene in cancer progression. Genomics Inform 2019;17:e36. https://doi.org/10.5808/GI.2019.17.4.e36
  25. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 2014;42:D92-D97. https://doi.org/10.1093/nar/gkt1248
  26. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res 2017;77:3965-3981. https://doi.org/10.1158/0008-5472.CAN-16-2634
  27. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet 2015;52:710-718. https://doi.org/10.1136/jmedgenet-2015-103334
  28. Liu Y, Xue M, Du S, Feng W, Zhang K, Zhang L, et al. Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. Nat Commun 2019;10:1637. https://doi.org/10.1038/s41467-019-09649-1
  29. Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci 2016;20:2285-2295.
  30. Zhao Y, Feng C, Li Y, Ma Y, Cai R. LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function. Mol Cell Biochem 2019;460:1-8. https://doi.org/10.1007/s11010-019-03564-1
  31. Ren J, Fu J, Ma T, Yan B, Gao R, An Z, et al. LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b. Cell Cycle 2018;17:1372-1380. https://doi.org/10.1080/15384101.2018.1482137
  32. Liu L, Liu L, Lu S. lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3. Int J Oncol 2019; 54:929-941.
  33. Li S, Mei Z, Hu HB, Zhang X. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol 2018;233:6679-6688. https://doi.org/10.1002/jcp.26325
  34. Wei S, Wang K, Huang X, Zhao Z, Zhao Z. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol 2019;33:2058738419859699.
  35. Zhen Q, Gao LN, Wang RF, Chu WW, Zhang YX, Zhao XJ, et al. LncRNA DANCR promotes lung cancer by sequestering miR216a. Cancer Control 2018;25:1073274818769849.
  36. Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ 2019;26:2329-2343. https://doi.org/10.1038/s41418-019-0304-y
  37. Liu H, Han L, Liu Z, Gao N. Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway. J Cell Physiol 2019;234:13843-13850. https://doi.org/10.1002/jcp.28064
  38. Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, et al. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer 2017;16:118. https://doi.org/10.1186/s12943-017-0685-9
  39. Tang Y, Wu L, Zhao M, Zhao G, Mao S, Wang L, et al. LncRNA SNHG4 promotes the proliferation, migration, invasiveness, and epithelial-mesenchymal transition of lung cancer cells by regulating miR-98-5p. Biochem Cell Biol 2019;97:767-776. https://doi.org/10.1139/bcb-2019-0065
  40. Yang J, Lin X, Jiang W, Wu J, Lin L. lncRNA LEF1-AS1 promotes malignancy in non-small-cell lung cancer by modulating the miR489/SOX4 axis. DNA Cell Biol 2019;38:1013-1021. https://doi.org/10.1089/dna.2019.4717
  41. Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett 2016;371:99-106. https://doi.org/10.1016/j.canlet.2015.11.024
  42. Li Z, Lu Q, Zhu D, Han Y, Zhou X, Ren T. Lnc-SNHG1 may promote the progression of non-small cell lung cancer by acting as a sponge of miR-497. Biochem Biophys Res Commun2018;506:632-640. https://doi.org/10.1016/j.bbrc.2018.10.086
  43. Yu W, Sun Z, Yang L, Han Y, Yue L, Deng L, et al. lncRNA PTAR promotes NSCLC cell proliferation, migration and invasion by sponging microRNA101. Mol Med Rep 2019;20:4168-4174.
  44. Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 2017;6:1614-1626. https://doi.org/10.1002/cam4.1087
  45. Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 2019;145:1613-1623. https://doi.org/10.1007/s00432-019-02899-y
  46. Liu C, Yang Z, Deng Z, Zhou Y, Gong Q, Zhao R, et al. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3. IUBMB Life 2018;70:536-546. https://doi.org/10.1002/iub.1752
  47. Acha-Sagredo A, Uko B, Pantazi P, Bediaga NG, Moschandrea C, Rainbow L, et al. Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. Br J Cancer 2020;122:1050-1058. https://doi.org/10.1038/s41416-020-0742-9
  48. Ma J, Yan H, Zhang J, Tan Y, Gu W. Long-chain non-coding RNA (lncRNA) MT1JP suppresses biological activities of lung cancer by regulating miRNA-423-3p/Bim axis. Med Sci Monit 2019;25:5114-5126. https://doi.org/10.12659/MSM.914387
  49. Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci 2019;23:7399-7407.
  50. Xia H, Xiu M, Gao J, Jing H. LncRNA PLAC 2 downregulated miR-21 in non-small cell lung cancer and predicted survival. BMC Pulm Med 2019;19:172. https://doi.org/10.1186/s12890-019-0931-6
  51. Liu X, Ma J, Xu F, Li L. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother 2018;99:9-17. https://doi.org/10.1016/j.biopha.2018.01.049
  52. Li Y, Zhao L, Zhao P, Liu Z. Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Cancer Biomark 2019;26:79-91. https://doi.org/10.3233/CBM-190142
  53. Zhang G, Wang Q, Zhang X, Ding Z, Liu R. LncRNA FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2 axis. Biomed Pharmacother 2019;118:109309. https://doi.org/10.1016/j.biopha.2019.109309
  54. Zhuan B, Lu Y, Chen Q, Zhao X, Li P, Yuan Q, et al. Overexpression of the long noncoding RNA TRHDE-AS1 inhibits the progression of lung cancer via the miRNA-103/KLF4 axis. J Cell Biochem 2019;120:17616-17624. https://doi.org/10.1002/jcb.29029
  55. Ao X, Jiang M, Zhou J, Liang H, Xia H, Chen G. lincRNAp21 inhibits the progression of nonsmall cell lung cancer via targeting miR175p. Oncol Rep 2019;41:789-800.
  56. Dong L, Li G, Li Y, Zhu Z. Upregulation of long noncoding RNA GAS5 inhibits lung cancer cell proliferation and metastasis via miR-205/PTEN axis. Med Sci Monit 2019;25:2311-2319. https://doi.org/10.12659/MSM.912581
  57. Mei Y, Si J, Wang Y, Huang Z, Zhu H, Feng S, et al. Long Noncoding RNA GAS5 suppresses tumorigenesis by inhibiting miR-23a rxpression in non-small cell lung cancer. Oncol Res 2017;25:1027-1037. https://doi.org/10.3727/096504016X14822800040451
  58. Xue Y, Ni T, Jiang Y, Li Y. Long noncoding RNA GAS5 inhibits tumorigenesis and enhances radiosensitivity by suppressing miR135b expression in non-small cell lung cancer. Oncol Res 2017;25:1305-1316. https://doi.org/10.3727/096504017X14850182723737
  59. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012;9:193-199. https://doi.org/10.7150/ijms.3635
  60. Buckley AM, Lynam-Lennon N, O'Neill H, O'Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol 2020;17:298-313. https://doi.org/10.1038/s41575-019-0247-2
  61. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. https://doi.org/10.1056/NEJMoa040938
  62. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-378. https://doi.org/10.1016/j.ejphar.2014.07.025
  63. Yang QS, Li B, Xu G, Yang SQ, Wang P, Tang HH, et al. Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10. J Cell Physiol 2019;234:11805-11821. https://doi.org/10.1002/jcp.27886
  64. Liu AM, Zhu Y, Huang ZW, Lei L, Fu SZ, Chen Y. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370. Eur Rev Med Pharmacol Sci 2019;23:5802-5814.
  65. Zhang J, Li W. Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in nonsmall cell lung cancer cells. Biosci Rep 2018;38:BSR20181599. https://doi.org/10.1042/BSR20181599
  66. Chen ZY, Liu HY, Jiang N, Yuan JM. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621. Eur Rev Med Pharmacol Sci 2019;23:9939-9946.
  67. Ma G, Zhu J, Liu F, Yang Y. Long noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p. DNA Cell Biol 2019;38:176-183. https://doi.org/10.1089/dna.2018.4462
  68. Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther 2019;20:261-271. https://doi.org/10.1080/15384047.2018.1529091
  69. Zeng F, Wang Q, Wang S, Liang S, Huang W, Guo Y, et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene 2020;39:293-307. https://doi.org/10.1038/s41388-019-0984-2